00:00Novartis has been committed for more than 20 years to the development of innovative drugs and new technological platforms
00:14that can somehow respond to all unsatisfied clinical needs with a high clinical load.
00:24Today we are very proud of this result that we have obtained thanks to an incessant collaboration with regulatory authorities
00:35that will finally be able to offer patients affected by prostatic carcinoma resistant to castration
00:44a new therapeutic opportunity to prolong life expectancy by maintaining and preserving a good quality of life as much as possible.
00:55One thing that makes us particularly proud is the fact that this new therapy with radioligands has a totally Italian brand.
01:06It was born from an idea of Professor Buono who, already at the beginning of the 2000s, through a small start-up,
01:15started this path in the field of therapy and the platform with radioligands.
01:22Today they are produced in Italy in the Ivrea production site, which is one of the few production sites in the world for this new technological platform
01:34and which is part of the Novartis group.
01:40Today we have reached an agreement with regulatory authorities and we expect this therapy to be available to all patients
01:54who have the necessary characteristics around March.
01:59We obviously hope that the path of access at the regional level can be rapid
02:07so that the therapeutic option becomes a reality for all patients effectively.
Comments